


This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Cancelled):
2. (Cancelled):
3. (Cancelled):
4. (Currently Amended): A compound of Formula I:



wherein

$R^1$  is alkyl having 1 to 8 carbon atoms wherein optionally one or more  $-CH_2CH_2-$  groups are replaced in each case by  $-CH=CH-$  or  $-C\equiv C-$  groups,

alkyl having 1 to 8 carbon atoms which is substituted one or more times by halogen, oxo or combinations thereof wherein optionally one or more  $-CH_2CH_2-$  groups are replaced in each case by  $-CH=CH-$  or  $-C\equiv C-$  groups,

cycloalkyl having 3 to 8 carbon atoms, which is unsubstituted or substituted one or more times by halogen, oxo, alkyl having 1 to 4 carbon atoms or combinations thereof,

a heterocyclic group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is an N, O or S atom which is unsubstituted or substituted one or more times by halogen, aryl, alkyl, alkoxy, cyano, halogenated alkyl, nitro, oxo, amino, alkylamino, dialkylamino, or combinations thereof,

aryl having 6 to 14 carbon atoms which is unsubstituted or substituted one or more times by halogen, CF<sub>3</sub>, OCF<sub>3</sub>, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, acylamido, and acyloxy, or combinations thereof,

arylalkyl having 8 to 16 carbon atoms which is unsubstituted or substituted one or more times by halogen, CF<sub>3</sub>, OCF<sub>3</sub>, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, acylamido, and acyloxy, or combinations thereof,

a partially unsaturated carbocyclic group having 5 to 14 carbon atoms, which is unsubstituted or substituted one or more times by halogen, alkyl, alkoxy, nitro, cyano, oxo, or combinations thereof ,

arylalkenyl having 8 to 16 carbon atoms, wherein the alkenyl portion has up to 5 carbon atoms, which is unsubstituted or substituted one or more times by halogen, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, acylamido, and acyloxy, or combinations thereof;

a heterocyclic-alkyl group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is an N, O or S atom, which is unsubstituted or substituted one or more times in the heterocyclic portion by halogen, aryl, alkyl, alkoxy, cyano, halogenated alkyl, nitro, oxo, amino, alkylamino, dialkylamino, carboxy or combinations thereof and/or substituted in the alkyl portion by halogen, oxo, cyano, or combinations thereof, or

cycloalkylalkyl having 4 to 16 carbon atoms which is unsubstituted or substituted one or more times by halogen, oxo, alkyl or combinations thereof,

R<sup>2</sup> is alkyl having 1 to 4 carbon atoms, which is unsubstituted or substituted one or more times by halogen;

R<sup>3</sup> is H,

~~alkyl having 1 to 8 carbon atoms wherein optionally one or more -CH<sub>2</sub>CH<sub>2</sub>- groups are replaced in each case by -CH=CH- or -C≡C- groups,~~

~~alkyl having 1 to 8 carbon atoms which is substituted one or more times by halogen, oxo, or combinations thereof wherein optionally one or more -CH<sub>2</sub>CH<sub>2</sub>- groups are replaced in each case by -CH=CH- or -C≡C- groups,~~

~~cycloalkyl having 3 to 8 carbon atoms, which is unsubstituted or substituted one or more times by halogen, oxo, alkyl, or combinations thereof,~~

~~arylalkyl having 7 to 16 carbon atoms, which is unsubstituted or substituted one or more times by halogen, alkyl, hydroxy, alkoxy, nitro, methylenedioxy,~~

~~ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenyl, phenoxy, and acyloxy, or combinations thereof,~~

~~heterocyclic alkyl group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is an N, O or S atom, which is unsubstituted or substituted one or more times in the heterocyclic portion by halogen, aryl, alkyl, alkoxy, cyano, halogenated alkyl, nitro, oxo, amino, alkylamino, dialkylamino, carboxy or combinations thereof and/or substituted in the alkyl portion by halogen, oxo, cyano, or combinations thereof,~~

~~alkoxyalkyl having 3 to 8 carbon atoms,~~

~~is phenpropyl, -C(O)R<sup>4</sup>, -(CH<sub>2</sub>)<sub>n</sub>C(O)R<sup>4</sup>, -(CH<sub>2</sub>)<sub>n</sub>OR<sup>5</sup>, -(CH<sub>2</sub>)<sub>n</sub>SR<sup>5</sup>, -(CH<sub>2</sub>)<sub>n</sub>SO<sub>2</sub>R<sup>4</sup>, -(CH<sub>2</sub>)<sub>n</sub>NR<sup>5</sup>R<sup>6</sup>, -CH<sub>2</sub>CO<sub>2</sub>R<sup>5</sup>, -CH<sub>2</sub>CONR<sup>6</sup>R<sup>5</sup>, -CH<sub>2</sub>CONHR<sup>5</sup>, -(CH<sub>2</sub>)<sub>n</sub>NR<sup>6</sup>SO<sub>2</sub>R<sup>4</sup>, -(CH<sub>2</sub>)<sub>n</sub>NR<sup>6</sup>COR<sup>4</sup>, or -CH<sub>2</sub>CONHSO<sub>2</sub>R<sup>4</sup>;~~

R<sup>4</sup> is alkyl having 1 to 12 carbon atoms which is unsubstituted or substituted one or more times by halogen, oxo, or combinations thereof wherein optionally one or more -CH<sub>2</sub>CH<sub>2</sub>- groups are replaced in each case by -CH=CH- or -C≡C- groups,

alkoxyalkyl having 3 to 8 carbon atoms which is unsubstituted or substituted one or more times by halogen, oxo, or combinations thereof wherein optionally one or more -CH<sub>2</sub>CH<sub>2</sub>- groups are replaced in each case by -CH=CH- or -C≡C- groups,

cycloalkyl having 3 to 8 carbon atoms, which is unsubstituted or substituted one or more times by halogen, oxo, alkyl, or combinations thereof,

cycloalkylalkyl having 4 to 16 carbon atoms, which is unsubstituted or substituted one or more times by halogen, oxo, alkyl or combinations thereof,

aryl having 6 to 14 carbon atoms, which is unsubstituted or substituted one or more times by halogen, CF<sub>3</sub>, OCF<sub>3</sub>, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, alkylsulphonamido, arylsulphonamido, halogenated arylsulphonamido, phenoxy, acylamido, and acyloxy, or combinations thereof,

arylalkyl having 8 to 16 carbon atoms, which is unsubstituted or substituted one or more times by halogen, CF<sub>3</sub>, OCF<sub>3</sub>, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, aminosulphonyl, phenoxy, acylamido, and acyloxy, or combinations thereof,

a heterocyclic group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is a N, O or S atom, which is unsubstituted or substituted one or more times by halogen, aryl, alkyl, cycloalkyl, cycloalkylalkyl, alkoxy, alkoxyalkyl, cyano, halogenated alkyl, halogenated alkoxy, nitro, oxo, amino, alkylamino, dialkylamino, aminosulphonyl, heterocycle, heterocyclic-alkyl, or combinations thereof, or

a heterocyclic-alkyl group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is an N, O or S atom, which is unsubstituted or substituted one or more times in the heterocyclic portion by halogen, aryl, alkyl, alkoxy, cyano, halogenated alkyl, nitro, oxo, amino, alkylamino, dialkylamino, carboxy or combinations thereof

and/or substituted in the alkyl portion by halogen, oxo, cyano, or combinations thereof; and

R<sup>5</sup> is H,

~~alkyl having 1 to 12 carbon atoms wherein optionally one or more~~  
~~CH<sub>2</sub>CH<sub>2</sub> groups are replaced in each case by CH=CH or C≡C groups,~~

~~alkyl having 1 to 12 carbon atoms which is substituted one or more times by~~  
~~halogen, oxo, or combinations thereof wherein optionally one or more~~  
~~CH<sub>2</sub>CH<sub>2</sub> groups are replaced in each case by CH=CH or C≡C groups,~~

is alkoxyalkyl having 3 to 8 carbon atoms which is unsubstituted or substituted one or more times by halogen, oxo, or combinations thereof wherein optionally one or more -CH<sub>2</sub>CH<sub>2</sub>- groups are replaced in each case by -CH=CH- or -C≡C- groups,

cycloalkyl having 3 to 8 carbon atoms, which is unsubstituted or substituted one or more times by halogen, oxo, alkyl, or combinations thereof,

cycloalkylalkyl having 4 to 16 carbon atoms which is unsubstituted or substituted one or more times by halogen, oxo, alkyl or combinations thereof,

aryl having 6 to 14 carbon atoms, which is unsubstituted or substituted one or more times by halogen, CF<sub>3</sub>, OCF<sub>3</sub>, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, alkylsulphonamido, arylsulphonamido, halogenated arylsulphonamido, phenoxy, acylamido, and acyloxy, or combinations thereof,

arylalkyl having 8 to 16 carbon atoms, which is unsubstituted or substituted one or more times by halogen, CF<sub>3</sub>, OCF<sub>3</sub>, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, aminosulphonyl, phenoxy, acylamido, and acyloxy, or combinations thereof,

a heterocyclic group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is a N, O or S atom, which is unsubstituted or substituted one or more times by halogen, aryl, alkyl, cycloalkyl, cycloalkylalkyl, alkoxy, alkoxyalkyl, cyano, halogenated alkyl, halogenated alkoxy, nitro, oxo, amino, alkylamino, dialkylamino, aminosulphonyl, heterocycle, heterocyclic-alkyl, or combinations thereof, or

a heterocyclic-alkyl group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is an N, O or S atom, which is unsubstituted or substituted one or more times in the heterocyclic portion by halogen, aryl, alkyl, alkoxy, cyano, halogenated alkyl, nitro, oxo, amino, alkylamino, dialkylamino, carboxy or combinations thereof and/or substituted in the alkyl portion by halogen, oxo, cyano, or combinations thereof;

R<sup>6</sup> is H,

alkyl having 1 to 12 carbon atoms wherein optionally one or more -CH<sub>2</sub>CH<sub>2</sub>- groups are replaced in each case by -CH=CH- or -C≡C- groups,

alkyl having 1 to 12 carbon atoms which is substituted one or more times by halogen, oxo, or combinations thereof wherein optionally one or more -CH<sub>2</sub>CH<sub>2</sub>-

groups are replaced in each case by  $-\text{CH}=\text{CH}-$  or  $-\text{C}\equiv\text{C}-$  groups,

alkoxyalkyl having 3 to 8 carbon atoms which is unsubstituted or substituted one or more times by halogen, oxo, or combinations thereof wherein optionally one or more  $-\text{CH}_2\text{CH}_2-$  groups are replaced in each case by  $-\text{CH}=\text{CH}-$  or  $-\text{C}\equiv\text{C}-$  groups,

cycloalkyl having 3 to 8 carbon atoms, which is unsubstituted or substituted one or more times by halogen, oxo, alkyl, or combinations thereof,

cycloalkylalkyl having 4 to 16 carbon atoms which is unsubstituted or substituted one or more times by halogen, oxo, alkyl or combinations thereof,

aryl having 6 to 14 carbon atoms, which is unsubstituted or substituted one or more times by halogen,  $\text{CF}_3$ ,  $\text{OCF}_3$ , alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, acylamido, and acyloxy, or combinations thereof,

arylalkyl having 8 to 16 carbon atoms, which is unsubstituted or substituted one or more times by halogen,  $\text{CF}_3$ ,  $\text{OCF}_3$ , alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, phenoxy, acylamido, and acyloxy, or combinations thereof;

a heterocyclic group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is a N, O or S atom, which is unsubstituted or substituted one or more times by halogen, aryl, alkyl, alkoxy, alkoxycarbonyl, cyano, halogenated alkyl, nitro, oxo, amino, alkylamino, dialkylamino, or combinations thereof, or



a heterocyclic-alkyl group, which is saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is an N, O or S atom, which is unsubstituted or substituted one or more times in the heterocyclic portion by halogen, aryl, alkyl, alkoxy, cyano, halogenated alkyl, nitro, oxo, amino, alkylamino, dialkylamino, carboxy or combinations thereof and/or substituted in the alkyl portion by halogen, oxo, cyano, or combinations thereof;

n is 0 or 1; and

pharmaceutically acceptable salts thereof;

wherein when  $R^3$  is  $-\text{CH}_2\text{CONR}^6\text{R}^5$ ,  $R^5$  is benzyl, thiazolyl, benzoxazolyl, **benzthiazolyl**, benzimidazolyl, benzothiazolyl, tetrahydroisoquinolinyl, thiadiazolyl, indolyl, indanyl, benzodioxanyl,  $-\text{CH}_2$ -benzothiazolyl, or  $-\text{CH}_2$ -pyridinyl, which in each case is substituted or unsubstituted.

with the proviso that:

(a) ~~when  $R^2$  is  $\text{CH}_3$  and  $R^3$  is H, then  $R^1$  is not methyl, ethyl, n-propyl, isopropyl, sec-butyl, n-butyl, isobutyl, neopentyl, n-pentyl, 2-methylbutyl, isopentyl, n-hexyl, phenyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopentenyl, methylcyclopentyl, cyclopropylmethyl, cyclopentylmethyl, 2-propenyl, 2-propynyl, 3-methyl-2-butenyl, N-substituted 2-piperazinylethyl, norbornyl, 3-tetrahydrofuryl, 2-tetrahydrofuryl, 3-tetrahydrothienyl, 2-oxacyclopropyl, 2-oxacyclopentyl, 3-oxacyclopentyl, 2-chloroethyl, 2-bromoethyl, 2,2,2-trifluoroethyl, 3-bromopropyl, 3-chloropropyl, or 4-bromobutyl;~~

~~(b) when  $R^1$  is cyclopentyl, and  $R^2$  is methyl, then  $R^3$  is not H, acetyl, benzyl, 4-hydroxybenzyl, 4-acetoxybenzyl, 4-bromobenzyl, 3,4-dimethoxybenzyl, 4-methylthiobenzyl, 4-cyanobenzyl, 2-aminobenzyl, 3-aminobenzyl, 4-aminobenzyl, 4-dimethylaminobenzyl, 2,4-diaminobenzyl, 4-amino-3,5-dimethoxybenzyl, 3-carboxybenzyl, 3-methoxycarbonylbenzyl, 4-methoxycarbonylbenzyl, 4-methylsulfinylbenzyl, 4-methylsulfonylbenzyl, 2-nitrobenzyl, 3-nitrobenzyl, 4-nitrobenzyl, 2,4-dinitrobenzyl, 2-nitro-4-aminobenzyl, 2-amino-4-nitrobenzyl, morpholinoethyl, 2-pyridylmethyl, 3-pyridylmethyl, 4-pyridylmethyl, 4-(6-fluoroquinolyl)methyl, 2-(7-chloroquinolyl)methyl, 2-imidazolylmethyl, or substituted imidazolylmethyl;~~

~~(c) when  $R^1$  is  $\text{CH}_3$ , and  $R^3$  is H, then  $R^2$  is not methyl, ethyl, or butyl;~~

~~(d) when  $R^3$  is H, then  $R^1$  and  $R^2$  are not both ethyl or isobutyl; and~~

~~(e) when  $R^1$  and  $R^2$  are both difluoromethyl, then  $R^3$  is not 4-aminobenzyl, or 4-amino-3,5-dimethoxybenzyl.~~

5. (Cancelled):

6. (Cancelled):

7. (Cancelled):

8. (Currently Amended): A compound according to claim 4, wherein said compound is selected from:

~~(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-2-pyrrolidone-1-acetic acid,~~  
~~(4S)-1-(N-Methoxycarbonylmethyl)-4-(4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-2-pyrrolidone,~~  
~~(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-1-[N-(2-methylphenyl)-(N-methyl)aminocarbonylmethyl]-2-pyrrolidone,~~  
~~(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-1-[N-(2-(6-methylpyridyl)-(N-methyl)aminocarbonylmethyl)-2-pyrrolidone,~~  
~~(4S)-1-[N-(2,3-Difluorophenyl)-(N-methyl)aminocarbonylmethyl]-4-(4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-2-pyrrolidone,~~  
~~(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-1-[N-(phenylaminocarbonylmethyl)-2-pyrrolidone,~~  
~~(4S)-1-[N-(4,5-Dimethylthiazol)-2-yl]aminocarbonylmethyl]-4-(4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-2-pyrrolidone,~~  
~~(4S)-1-[N-(3-Chlorophenyl)aminocarbonylmethyl]-4-(4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-2-pyrrolidone,~~  
~~(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-1-[N-(3-methoxycarbonylphenyl)aminocarbonylmethyl]-2-pyrrolidone,~~  
~~(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-1-[N-(3-phenpropyl)]-2-pyrrolidone,~~  
~~(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-1-[N-(2-phenoxyethyl)]-2-pyrrolidone,~~  
~~(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-1-[N-(2-phenthioethyl)]-2-pyrrolidone,~~  
~~(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-1-(N-phensulfonylaminocarbonylmethyl)-2-pyrrolidone,~~  
~~(4S)-1-[N-(2,3-Difluorophenyl)-(N-ethyl)aminocarbonylmethyl]-4-(4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-2-pyrrolidone,~~  
~~(4S)-1-[N-(2,3-Difluorophenyl)-(N-isopropyl)aminocarbonylmethyl]-4-(4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-2-pyrrolidone,~~  
~~(4S)-1-[N-(2,3-Difluorophenyl)-(N-cyclopropylmethyl)aminocarbonylmethyl]-4-(4-methoxy-3-~~

(3R)-tetrahydrofuranyloxyphenyl)-2-pyrrolidone,  
 (4S)-1-[N-(4-Carboxyphenyl)aminocarbonylmethyl]-4-(4-methoxy-3-(3R)-  
 tetrahydrofuranyloxyphenyl)-2-pyrrolidone,  
 (4S)-1-[N-(3-Fluorophenyl)aminocarbonylmethyl]-4-(4-methoxy-3-(3R)-  
 tetrahydrofuranyloxyphenyl)-2-pyrrolidone,  
 (4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-1-[N-(2-  
 thiazolyl)aminocarbonylmethyl]-2-pyrrolidone,  
 (4S)-1-[N-(4-Methoxyphenyl)aminocarbonylmethyl]-4-(4-methoxy-3-(3R)-  
 tetrahydrofuranyloxyphenyl)-2-pyrrolidone,  
 (4S)-1-[N-(2,6-Dimethylphenyl)aminocarbonylmethyl]-4-(4-methoxy-3-(3R)-  
 tetrahydrofuranyloxyphenyl)-2-pyrrolidone,  
 (4S)-1-[N-(4-Isopropylphenyl)aminocarbonylmethyl]-4-(4-methoxy-3-(3R)-  
 tetrahydrofuranyloxyphenyl)-2-pyrrolidone,  
 (4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-1-[N-(3,4-  
 methylenedioxyphenyl)aminocarbonylmethyl]-2-pyrrolidone,  
 (4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-1-[N-(2-(4-  
 trifluoromethyl)pyridyl)aminocarbonylmethyl]-2-pyrrolidone,  
 (4S)-1-[N-(3-Carboxyphenyl)aminocarbonylmethyl]-4-(4-methoxy-3-(3R)-  
 tetrahydrofuranyloxyphenyl)-2-pyrrolidone,  
 (4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-1-[N-(2-phenylsulfonyl-ethyl)]-2-  
 pyrrolidone,  
 (4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-1-[N-(2-  
 methylphenyl)sulfonylaminocarbonylmethyl]-2-pyrrolidone,  
 (4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-1-[N-(2-(4-methoxyphenyl)oxyethyl)]-  
 2-pyrrolidone,  
 (4S)-1-[N-(2-(5-Chlorobenzoxazolyl)aminocarbonylmethyl)]-4-(4-methoxy-3-(3R)-  
 tetrahydrofuranyloxyphenyl)-2-pyrrolidone,  
 (4S)-1-[N-(2-(Benzthiazolyl)aminocarbonylmethyl)]-4-(4-methoxy-3-(3R)-  
 tetrahydrofuranyloxyphenyl)-2-pyrrolidone,

(4S)-1-[N-(2-(6-Fluorobenzthiazolyl)aminocarbonylmethyl)]-4-(4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-2-pyrrolidone,  
(4S)-1-[N-(2-(Benzimidazolyl)aminocarbonylmethyl)]-4-(4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-2-pyrrolidone, and

physiologically acceptable salts thereof, wherein in each case the compound can be in the form of a mixture of enantiomers such as the racemate, or a mixture of diastereomers, or can be in the form of a single enantiomer or a single diastereomer.

9. (Currently Amended): A compound according to claim 1, wherein said compound is selected from:

(4S)-1-[2-(3-Chlorophenoxy)ethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone,  
(4S)-1-[2-(4-Isopropylphenoxy)ethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone,  
(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-1-[N-(4-methylbenzothiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone,  
(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-1-[N-(5-methylthiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone,  
(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-1-[N-(6-methylbenzothiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone,  
(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-1-[N-(4-methoxybenzothiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone,  
(4S)-1-[N-(6-Ethoxycarbonylbenzothiazol-2-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone,  
(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-1-[N-(6-trifluoromethoxylbenzothiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone,  
(4S)-1-[N-(4-tert-Butylthiazol-2-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone,

(4S)-1-[2-(4-Isopropylphenylthio)ethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone,  
 (4S)-1-[2-(3-Chlorophenylthio)ethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone,  
 (4S)-1-[2-(2,3-Difluorophenoxy)ethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone,  
 (4S)-1-[N-(2,3-Difluorophenyl)-N-(2-methylpropyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone,  
 (4S)-1-[N-(4-Isopropoxyphenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone,  
 (4S)-1-[N-(4-Fluorophenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone,  
 (4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-1-[2-(1,2,3,4-tetrahydroisoquinoliny)carbonylmethyl]-2-pyrrolidone,  
 (4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-1-[1-(1,2,3,4-tetrahydroquinoliny)carbonylmethyl]-2-pyrrolidone,  
 (4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-1-[N-(4-trifluoromethoxyphenyl)aminocarbonylmethyl]-2-pyrrolidone,  
 (4S)-1-[N-(6-Fluorobenzothiazol-2-yl)-N-(methyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone,  
 (4S)-1-[2-(Benzothiazol-2-yl)oxyethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone,  
 (4S)-1-[2-(6-Fluorobenzothiazol-2-yl)thioethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone,  
 (4S)-1-[N-(6-Fluorobenzothiazol-2-yl)aminoethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone[,  
 (4S)-1-[N-(Benzothiazol-2-yl)aminoethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone,  
 (4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-N-[2-(2-oxopyrrolidin-1-yl)ethyl]-4-

phenoxybenzamide,

(4S)-1-[N-(3-Fluorophenyl)-N-(methyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone,

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-1-[N-(4-methoxyphenyl)-N-(methyl)aminocarbonylmethyl]-2-pyrrolidone,

(4S)-1-[N-(4-Isopropylphenyl)-N-(methyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone,

(4S)-1-[N-(3,4-Methylenedioxyphenyl)-N-(methyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone,

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-1-[N-(4-methylthiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone,

(4S)-1-[N-(4-tert-Butylphenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone,

(4S)-1-[N-(6-Chlorobenzothiazol-2-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone,

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-1-[N-methyl-N-(thiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone,

(4S)-1-[N-(Benzothiazol-2-yl)-N-(cyclopropylmethyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone,

(4S)-1-[N-(Indol-2-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone,

(4S)-1-[N-(Indan-2-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone,

(4S)-1-[N-(5-Chlorothiazol-2-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone,

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-1-[N-(4-phenylthiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone,

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-1-[N-(6-methoxybenzothiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone,

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-N-[2-(2-oxopyrrolidin-1-yl)ethyl]benzamide,  
 (4S)-2,3-Difluoro-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-N-[2-(2-oxopyrrolidin-1-yl)ethyl]-benzamide,  
 (4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-N-[2-(2-oxopyrrolidin-1-yl)ethyl]-4-methoxybenzamide,  
 (4S)-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-1-[2-(4-trifluoromethylphenoxy)ethyl]-2-pyrrolidone,  
 (4S)-1-[N-(5-Cyclopropyl-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone,  
 (4S)-1-[N-(Benzothiazol-6-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone,  
 (4S)-1-[N-(4-Ethoxycarbonylthiazol-2-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone,  
 (4S)-1-[N-(5-tert-Butyl-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone,  
 (4S)-1-[N-Cyclopropylmethyl-N-(6-fluorobenzothiazol-2-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone,  
 (4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-1-(2-oxo-2-phenylethyl)-2-pyrrolidone,  
 (4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-1-(2-oxo-2-(4-methoxyphenyl)ethyl)-2-pyrrolidone,  
 (4S)-1-[N-(2,4-Dimethoxyphenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone,  
 (4S)-1-[N-(3,5-Dimethoxyphenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone,  
 (4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-1-[N-(2,2,3,3-tetrafluorobenzo-1,4-dioxan-6-yl)aminocarbonylmethyl]-2-pyrrolidone,  
 (4S)-1-[N-(3,4-(Difluoromethylene)dioxyphenyl)-N-methylaminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone,



~~(4S)-1-[N-(3-Fluoro-4-methoxyphenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone,~~  
~~(4S)-1-[N-(1,4-Benzodioxan-6-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone,~~  
~~(4S)-1-[N-(2-Fluorophenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone,~~  
~~(4S)-1-[N-(3,4-Dimethoxyphenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone,~~  
~~(4S)-1-[N-(3,4-Difluorophenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone,~~  
~~(4S)-1-[N-(4-Methanesulfonamidophenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone,~~  
~~(4S)-1-[N-(4-(4-Fluorophenyl)thiazol-2-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone,~~  
~~(4S)-1-[N-(3-Fluoro-4-methylphenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone,~~  
~~(4S)-1-[N-(4,6-Difluorobenzothiazol-2-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone,~~  
~~(4S)-1-[N-(4-Carboxythiazol-2-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone,~~  
~~(4R)-1-[N-(3-Fluorophenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3S)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone,~~  
~~(4S)-1-[2-(2-Fluorophenylthio)ethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone,~~  
~~(4S)-1-[2-(3-Fluorophenylthio)ethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone [431.52 MW; 432.1 M+H],~~  
~~(4S)-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-1-[2-(4-methoxyphenylthio)ethyl]-2-pyrrolidone,~~  
~~(4S)-1-[N-(4-Carboxy-3-fluorophenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-~~

tetrahydrofuranyloxyphenyl]-2-pyrrolidone,  
 (4S)-1-[N-(4-Ethanesulfonamidophenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-  
 tetrahydrofuranyloxyphenyl]-2-pyrrolidone,  
 (4S)-1-[N-(4-Benzenesulfonamidophenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-  
 tetrahydrofuranyloxyphenyl]-2-pyrrolidone,  
 (4S)-1-[N-(4-(4-Fluorobenzene)sulfonamidophenyl)aminocarbonylmethyl]-4-[4-methoxy-3-  
 (3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone,  
 (4S)-1-[N-(2,3-Difluorobenzyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-  
 tetrahydrofuranyloxyphenyl]-2-pyrrolidone,  
 (4S)-1-[N-(5-Cyclopropylmethyl-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-4-[4-methoxy-3-  
 (3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone,  
 (4S)-1-[N-(6-Ethylpyridin-2-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-  
 tetrahydrofuranyloxyphenyl]-2-pyrrolidone,  
 (4S)-1-[N-(3-Fluorobenzyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-  
 tetrahydrofuranyloxyphenyl]-2-pyrrolidone,  
 (4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-1-[N-(2-  
 methylbenzyl)aminocarbonylmethyl]-2-pyrrolidone,  
 (4S)-1-[N-(4-Methanesulfonylbenzyl)aminocarbonylmethyl]-4-[4-Methoxy-3-(3R)-  
 tetrahydrofuranyloxyphenyl]-2-pyrrolidone,  
 (4S)-1-[N-(4-Aminosulfonylbenzyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-  
 tetrahydrofuranyloxyphenyl]-2-pyrrolidone,  
 (4S)-1-[N-(Benzothiazol-2-yl)methylaminocarbonylmethyl]-4-[4-methoxy-3-(3R)-  
 tetrahydrofuranyloxyphenyl]-2-pyrrolidone,  
 (4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-1-[N-(3-methylpyridin-2-  
 yl)methylaminocarbonylmethyl]-2-pyrrolidone,  
 (4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-1-[N-(5-trifluoromethyl-1,3,4-  
 thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone,  
 (4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-1-[N-(5-(4-pyridyl)-1,3,4-thiadiazol-2-  
 yl)aminocarbonylmethyl]-2-pyrrolidone,

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-1-[N-(4-(3-pyridyl)thiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone,

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-1-[N-(4-(2-pyridyl)thiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone,

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-1-[N-(4-(4-pyridyl)thiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone,

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-1-[N-(5-(4-pyridyl)-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-1-[N-(5-ethoxycarbonyl-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-1-[N-(5-methoxycarbonyl-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-1-[N-(5-(3,4-methylenedioxyphenyl)-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-1-[N-(5-(2-thienyl)-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-1-[N-(5-(2-thienylmethyl)-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-1-[N-(5-(2-propyl)-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-1-[N-(5-(2-pyrazinyl)-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-1-[N-(5-methoxymethyl-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-1-[N-(5-(2-tetrahydrofuranyl)-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-1-[N-(5-aminosulfonyl-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-1-[N-(5-(4-methoxyphenyl)-1,3,4-

thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone  
 (4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-1-[N-(5-(4-methoxyphenyloxymethyl)-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone  
 (4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-1-[N-(5-(4-morpholinylcarbonylmethyl)-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone  
 (4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-1-[N-(5-(1-piperidinylcarbonylmethyl)-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone  
 (4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-1-[N-(5-(1-pyrrolidinylcarbonylmethyl)-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone  
 (4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-1-[N-(5-(4-piperidinyl)-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone  
 (4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-1-[N-(5-(4-(N-tertbutyloxycarbonyl)piperidinyl)-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone  
 (4S)-1-[N-(2,3-Difluorophenylaminocarbonylmethyl)-4-(4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-2-pyrrolidone, and  
~~(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-1-[N-(4-ethoxycarbonylphenyl)aminocarbonylmethyl]-2-pyrrolidone;~~  
~~(4S)-1-[N-(4-tert-butyloxycarbonyl-3-fluorophenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone; and~~

physiologically acceptable salts thereof, wherein in each case the compound can be in the form of a mixture of enantiomers such as the racemate, or a mixture of diastereomers, or can be in the form of a single enantiomer or a single diastereomer.

10. (Previously Presented): A pharmaceutical composition comprising a compound of Claim 1 and a pharmaceutically acceptable carrier.

11. (Original): A composition of claim 10, wherein the compound is provided in a unit dosage of 0.1 - 50 mg.

12. (Withdrawn): A method for effecting PDE4 enzyme inhibition, enhancing cognition and/or treating psychosis in a patient comprising administering to said patient an effective amount of a compound according to Claim 1.

13. (Withdrawn) A method according to claim 12, wherein said compound is administered in an amount of 0.01-100 mg/kg of body weight/day.

14. (Withdrawn) A method according to claim 12, wherein said patient is a human.

15. (Withdrawn) A method of claim 12, wherein the patient is suffering from cognition impairment or decline.

16. (Withdrawn) A method according to claim 12, wherein said patient is suffering from memory impairment.

17. (Withdrawn; Currently Amended) A method according to claim 16, wherein said patient is suffering from memory impairment due to Alzheimer's disease, schizophrenia, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeldt-Jakob Creutzfeld-Jakob disease, HIV, cardiovascular disease, head trauma or age-related cognitive decline.

18. (Withdrawn) A method according to claim 16, wherein said patient is suffering from memory impairment due to dementia.

19. (Withdrawn) A method according to claim 16, wherein said patient is suffering from memory impairment Alzheimer's disease, schizophrenia, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeldt-Jakob disease, depression, aging, head trauma, stroke, CNS hypoxia, cerebral senility, multiinfarct dementia, an acute neuronal disease, HIV or a cardiovascular disease.

20. (Withdrawn) A method according to claim 12, wherein said patient is suffering from a psychosis.

21. (Withdrawn) The method of claim 20, wherein the psychosis is schizophrenia, bipolar or manic depression, major depression, drug addiction or morphine dependence.

22. (Withdrawn) A method for treating a patient having a disease involving decreased cAMP levels comprising administering to said patient an effective amount of a compound according to Claim 1.

23. (Withdrawn) A method of claim 12, wherein the patient is treated to effect PDE4 enzyme inhibition.

24. (Withdrawn) A method of treating a patient suffering from an allergic or inflammatory disease comprising administering to said patient an effective amount of a compound according to Claim 1.

25. (Withdrawn; Currently Amended) A method of claim 24, wherein the patient is suffering ~~suffering~~ from chronic obstructive pulmonary disease.

26. (Withdrawn) A method of treating a patient suffering from neurodegeneration resulting from a disease or injury comprising administering to said patient an effective amount of a compound according to Claim 1.

27. (Withdrawn) The method of claim 26, wherein the disease or injury is stroke, spinal cord injury, neurogenesis, Alzheimer's disease, multiple sclerosis, amyloidosis (ALS), or multiple systems atrophy (MSA).

28. (Previously Presented): A compound according to claim 9, wherein said compound is 4-[4-Methoxy-3-tetrahydrofuranyloxyphenyl]-1-[N-(5-(4-methoxyphenyl)-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone or a physiologically acceptable salt thereof, wherein the compound can be in the form of a mixture of enantiomers, or a mixture of diastereomers, or can be in the form of a single enantiomer or a single diastereomer.

29. (Previously Presented): A compound according to claim 9, wherein said compound is (4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-1-[N-(5-(4-methoxyphenyl)-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone or a physiologically acceptable salt thereof.

30. (Previously Presented): A compound according to claim 4, wherein  $R^1$  is optionally substituted cyclopentyl, optionally substituted phenethyl, 3-tetrahydrofuranyl,  $CHF_2$ , or cyclopropylmethyl.

31. (Previously Presented): A compound according to claim 4, wherein  $R^2$  is  $CHF_2$  and  $CH_3$ .

32. (Currently Amended): A compound according to claim 4, wherein  $R^3$  is - $(CH_2)_nOR^5$ , - $(CH_2)_nSR^5$ , - $(CH_2)_nSO_2R^4$ , - $(CH_2)_nNR^5R^6$ , - $CH_2CO_2R^5$ , - $CH_2CH_2CO_2R^5$ , - $CH_2CONR^6R^5$ , - $CH_2CONHR^5$ , - $(CH_2)_nNR^6SO_2R^4$ , - $(CH_2)_nNR^6COR^4$ , or - $CH_2CONHSO_2R^4$ .

33. (Currently Amended): A compound according to claim 4, wherein  $R^3$  is  $CH_2CONHR^5$  or  $CH_2CONR^6R^5$ .

34. (Previously Presented): A compound according to claim 33, wherein  $R^5$  is

2-thiazolyl which is unsubstituted or substituted by F, Cl, CF<sub>3</sub>, methoxymethyl, isopropyl, isobutyl, t-butyl, , carboxy, alkoxycarbonyl, cyclopropyl, cyclopropylmethyl, phenyl, pyridyl, piperidinyl, 3,4-methylenedioxyphenyl, thienyl, pyrazinyl, tetrahydrofuranyl, morpholinyl, pyrrolidinyl, or thienylmethyl, or

1,3,4-thiadiazolyl which is unsubstituted or substituted by F, Cl, CF<sub>3</sub>, methyl, methoxymethyl, isopropyl, isobutyl, t-butyl, , carboxy, alkoxycarbonyl, cyclopropyl, cyclopropylmethyl, phenyl, pyridyl, piperidinyl, 3,4-methylenedioxyphenyl, thienyl, pyrazinyl, tetrahydrofuranyl, morpholinyl, pyrrolidinyl, or thienylmethyl.

35. (Previously Presented): A compound according to claim 4, wherein  
R<sup>1</sup> is CHF<sub>2</sub> cycloalkyl, cycloalkylalkyl, heterocyclic group, or heterocyclicalkyl group;  
R<sup>2</sup> is CH<sub>3</sub> or CHF<sub>2</sub>;  
R<sup>3</sup> is CH<sub>2</sub>CONHR<sup>5</sup>; and  
R<sup>5</sup> is substituted or unsubstituted 1,3,4-thiadiazolyl.

36. (Previously Presented): A compound according to claim 35, wherein R<sup>1</sup> is cyclopentyl, tetrahydrofuran, cyclopropylmethyl or CHF<sub>2</sub>.

37. (New): A compound selected from:  
(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-2-pyrrolidone-1-acetic acid,  
(4S)-1-(N-Methoxycarbonylmethyl)-4-(4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-2-pyrrolidone;  
(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-1-[N-(2-methylphenyl)-(N-methyl)aminocarbonylmethyl]-2-pyrrolidone;  
(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-1-[N-(2-(6-methylpyridyl)-(N-methyl)aminocarbonylmethyl)-2-pyrrolidone;  
(4S)-1-[N-(2,3-Difluorophenyl)-(N-methyl)aminocarbonylmethyl]-4-(4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-2-pyrrolidone;  
(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-1-[N-



(phenylaminocarbonylmethyl)]-2-pyrrolidone;

(4S)-1-[N-(3-Chlorophenyl)aminocarbonylmethyl]-4-(4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-2-pyrrolidone;

(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-1-[N-(3-methoxycarbonylphenyl)aminocarbonylmethyl]-2-pyrrolidone;

(4S)-1-[N-(2,3-Difluorophenyl-(N-ethyl)aminocarbonylmethyl)]-4-(4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-2-pyrrolidone;

(4S)-1-[N-(2,3-Difluorophenyl-(N-isopropyl)aminocarbonylmethyl)]-4-(4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-2-pyrrolidone;

(4S)-1-[N-(2,3-Difluorophenyl-(N-cyclopropylmethyl)aminocarbonylmethyl)]-4-(4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-2-pyrrolidone;

(4S)-1-[N-(4-Carboxyphenyl)aminocarbonylmethyl]-4-(4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-2-pyrrolidone;

(4S)-1-[N-(3-Fluorophenyl)aminocarbonylmethyl]-4-(4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-2-pyrrolidone;

(4S)-1-[N-(4-Methoxyphenyl)aminocarbonylmethyl]-4-(4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-2-pyrrolidone;

(4S)-1-[N-(2,6-Dimethylphenyl)aminocarbonylmethyl]-4-(4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-2-pyrrolidone;

(4S)-1-[N-(4-Isopropylphenyl)aminocarbonylmethyl]-4-(4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-2-pyrrolidone;

(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-1-[N-(3,4-methylenedioxyphenyl)aminocarbonylmethyl]-2-pyrrolidone;

(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-1-[N-(2-(4-trifluoromethyl)pyridyl)aminocarbonylmethyl]-2-pyrrolidone;

(4S)-1-[N-(3-Carboxyphenyl)aminocarbonylmethyl]-4-(4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-2-pyrrolidone; and

physiologically acceptable salts thereof, wherein in each case the compound can be in the form of a mixture of enantiomers such as the racemate, or a mixture of diastereomers, or can be

in the form of a single enantiomer or a single diastereomer.

38. (New): A compound according to claim 37, wherein said compound is selected from:

(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-1-[N-(2-(6-methylpyridyl)-(N-methyl)aminocarbonylmethyl)]-2-pyrrolidone;

(4S)-1-[N-(2,3-Difluorophenyl)-(N-methyl)aminocarbonylmethyl]-4-(4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-2-pyrrolidone;

(4S)-1-[N-(3-Fluorophenyl)aminocarbonylmethyl]-4-(4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-2-pyrrolidone;

(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-1-[N-(2-(4-trifluoromethyl)pyridyl)aminocarbonylmethyl]-2-pyrrolidone;

(4S)-1-[N-(3-Carboxyphenyl)aminocarbonylmethyl]-4-(4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-2-pyrrolidone; and

physiologically acceptable salts thereof, wherein in each case the compound can be in the form of a mixture of enantiomers such as the racemate, or a mixture of diastereomers, or can be in the form of a single enantiomer or a single diastereomer.

39. (New): A compound selected from:

(4S)-1-[N-(2,3-Difluorophenyl)-N-(2-methylpropyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone;

(4S)-1-[N-(4-Isopropyloxyphenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone;

(4S)-1-[N-(4-Fluorophenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone;

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-1-[N-(4-trifluoromethoxyphenyl)aminocarbonylmethyl]-2-pyrrolidone;

(4S)-1-[N-(3-Fluorophenyl)-N-(methyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone;

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-1-[N-(4-methoxyphenyl)-N-(methyl)aminocarbonylmethyl]-2-pyrrolidone;

(4S)-1-[N-(4-Isopropylphenyl)-N-(methyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone;

(4S)-1-[N-(3,4-Methylenedioxyphenyl)-N-(methyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone;

(4S)-1-[N-(4-tert-Butylphenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone;

(4S)-1-[N-(2,4-Dimethoxyphenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone;

(4S)-1-[N-(3,5-Dimethoxyphenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone;

(4S)-1-[N-(3,4-(Difluoromethylene)dioxyphenyl)-N-methylaminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone;

(4S)-1-[N-(3-Fluoro-4-methoxyphenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone;

(4S)-1-[N-(2-Fluorophenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone;

(4S)-1-[N-(3,4-Dimethoxyphenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone,

(4S)-1-[N-(3,4-Difluorophenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone;

(4S)-1-[N-(4-Methanesulfonamidophenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone;

(4S)-1-[N-(3-Fluoro-4-methylphenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone,

(4R)-1-[N-(3-Fluorophenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3S)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone,

(4S)-1-[N-(4-Carboxy-3-fluorophenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-

tetrahydrofuranyloxyphenyl]-2-pyrrolidone;

(4S)-1-[N-(4-Ethanesulfonamidophenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone;

(4S)-1-[N-(4-Benzenesulfonamidophenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone;

(4S)-1-[N-(4-(4-Fluorobenzene)sulfonamidophenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone;

(4S)-1-[N-(6-Ethylpyridin-2-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone;

(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-1-[N-(4-ethoxycarbonylphenyl)aminocarbonylmethyl]-2-pyrrolidone,

(4S)-1-[N-(4-tert-butyloxycarbonyl-3-fluorophenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone and

physiologically acceptable salts thereof, wherein in each case the compound can be in the form of a mixture of enantiomers such as the racemate, or a mixture of diastereomers, or can be in the form of a single enantiomer or a single diastereomer.

40. (New): A compound according to claim 39, wherein said compound is selected from:

(4S)-1-[N-(2,3-Difluorophenyl)-N-(2-methylpropyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone,

(4S)-1-[N-(3-Fluorophenyl)-N-(methyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone,

(4S)-1-[N-(2-Fluorophenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone,

(4S)-1-[N-(3,4-Difluorophenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone,

(4S)-1-[N-(4-Methanesulfonamidophenyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone,

(4S)-1-[N-(6-Ethylpyridin-2-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone, and

physiologically acceptable salts thereof, wherein in each case the compound can be in the form of a mixture of enantiomers such as the racemate, or a mixture of diastereomers, or can be in the form of a single enantiomer or a single diastereomer.

41. (New): A pharmaceutical composition comprising a compound of Claim 37 and a pharmaceutically acceptable carrier.

42. (New): A pharmaceutical composition comprising a compound of Claim 38 and a pharmaceutically acceptable carrier.

43. (New): A pharmaceutical composition comprising a compound of Claim 39 and a pharmaceutically acceptable carrier.

44. (New): A pharmaceutical composition comprising a compound of Claim 40 and a pharmaceutically acceptable carrier.

45. (New): A compound according to claim 8, wherein said compound is selected from:

(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-1-(N-phensulfonylamino-carbonylmethyl)-2-pyrrolidone;

(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-1-[N-(2-thiazolyl)amino-carbonylmethyl]-2-pyrrolidone,

(4S)-4-(4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-1-[N-(2-methylphenyl)sulfonyl-

aminocarbonylmethyl]-2-pyrrolidone,

(4S)-1-[N-(2-(6-Fluorobenzthiazolyl)aminocarbonylmethyl)]-4-(4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl)-2-pyrrolidone, and

physiologically acceptable salts thereof, wherein in each case the compound can be in the form of a mixture of enantiomers such as the racemate, or a mixture of diastereomers, or can be in the form of a single enantiomer or a single diastereomer.

46. (New): A compound according to claim 9, wherein said compound is selected from:

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-1-[N-(4-methylbenzothiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone;

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-1-[N-(5-methylthiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone;

(4S)-1-[N-(4-tert-Butylthiazol-2-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone;

(4S)-1-[2-(4-Isopropylphenylthio)ethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone;

(4S)-1-[2-(3-Chlorophenylthio)ethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone;

(4S)-1-[N-(6-Fluorobenzothiazol-2-yl)-N-(methyl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone;

(4S)-1-[2-(Benzothiazol-2-yl)oxyethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone;

(4S)-1-[N-(Benzothiazol-2-yl)aminoethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone;

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-N-[2-(2-oxopyrrolidin-1-yl)ethyl]-4-phenoxybenzamide;

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-1-[N-(4-methylthiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone;

(4S)-1-[N-(5-Cyclopropyl-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone;

(4S)-1-[N-(5-tert-Butyl-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-2-pyrrolidone;

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-1-[N-(5-trifluoromethyl-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone;

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-1-[N-(5-(4-pyridyl)-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone;

(4S)-4-[4-Methoxy-3-(3R)-tetrahydrofuranyloxyphenyl]-1-[N-(5-methoxycarbonyl-1,3,4-thiadiazol-2-yl)aminocarbonylmethyl]-2-pyrrolidone; and

physiologically acceptable salts thereof, wherein in each case the compound can be in the form of a mixture of enantiomers such as the racemate, or a mixture of diastereomers, or can be in the form of a single enantiomer or a single diastereomer.